IRADIMED CORPORATION (NASDAQ:IRMD) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

IRADIMED CORPORATION (NASDAQ:IRMD) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 23, 2019, Iradimed Corporation (the “Company”) entered into the First Amended and Restated Separation Agreement (the “Agreement”) with John McCreery resulting from Mr. McCreery’s retirement.
to his Agreement, Mr. McCreery will continue to serve as the Company’s Chief Operating Officer through the period ending Monday, January 6, 2020 (the “Retirement Date”), will remain eligible to receive the 2019 annual bonus, and will receive a one-time addition of 40 hours to his total paid time-off balance. Additionally, the Company has agreed to accelerate the vesting of the third tranche of Mr. McCreery’s initial restricted stock unit award to his Retirement Date, amounting to 15,625 shares of the Company’s common stock.
This summary description is qualified in its entirety by reference to the First Amended and Restated Separation Agreement between the Company and Mr. McCreery, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
IRADIMED CORP Exhibit
EX-10.1 2 exhibit_10-1.htm First Amended and Restated SEPARATION AGREEMENT This First Amended and Restated Separation Agreement is between Iradimed Corporation (“Iradimed”) and John McCreery (“Employee”). As Employee desires to retire,…
To view the full exhibit click here

Story continues below

About IRADIMED CORPORATION (NASDAQ:IRMD)

IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, non-ferrous part and other features in order to deliver anesthesia and other IV fluids during various MRI procedures. MRI compatible IV infusion pump system includes the 3860+ MRI compatible IV infusion pump, single-use IV tubing sets, a non-magnetic pole and a lithium battery. In addition, it offers optional upgrade systems, including the 3865 Remote Display/Control, 3861 Side Car, Dose Error Reduction System (DERS) and SpO2 monitor.

An ad to help with our costs